How Can We Explain the American Dominance in Biomedical Research and Development?

Levitzki A. (2003) ‘The closure of Sugen’, Nature Biotechnology, 969 September.

Van Brunt J. (2004) ‘The licensing-go-round’, Signal Magazine..

The Economist (2004) ‘World in figures’, 53.

The Economist (2004) ‘The great illusion’, 30 September.

Boehm T. (2005) ‘The battle against nature — should we rethink our strategy fighting bacteria, parasites, viruses and cancer?’ manuscript in preparation.

Statistics on Science and Technology in Europe (2003) Eurostat..

UNICE and European Commission (2002) ‘DG research workshop’, Brussels, 6th November.

The Tufts Center for the Study of Drug Development, http://csdd.tufts.eduInfoServices/OutlookReports.asp.

Howard Hughes Medical Institute, http://www.hhmi.org.

Bodenheimer T. (2000) ‘Uneasy alliance: Clinical investigators and the pharmaceutical industry’, New England Journal of Medicine, 342, 1539–1544.

Lo B. Wolf L.E. Berkeley A. (2000) ‘Conflict-of-interest policies for investigators in clinical trials’, New England Journal of Medicine 343, 1616–1620.

Van McCrary S. Anderson C. B. Jakovljevic J. (2000) ‘A national survey of policies on disclosure of conflicts of interest in biomedical research’, New England Journal of Medicine, 343, 1621–1626.

Stein D. (2004) Buying in or Selling Out? The Commercialization of the American Research Industry. Rutgers University Press, NJ.

Council for Aid to Education, www.cae.org.

Charlemagne (2004) ‘Battling for brains: The parlous state of European universities’, The Economist, 25 September.

Programme for International Student Assessment (PISA), http://www.pisa.oecd.org/.

Coimbra Group, http://www.coimbra-group.be.

PISA op. cit..

Shanghai Jiao Tong University, Institute of Higher Education, http://ed.sjtu.edu.cn/rank/2004/statistics.htm.

Charlemagne (2004) op. cit..